StockData
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) stock

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$1.81−0.08 (-4.23%)

Close on Oct 30, 2026Market cap $150.97MP/E –Yield –

Earnings

Pyxis Oncology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 2, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
–
– on a year earlier
EPS, Q2 FY2026
-$0.40
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Pyxis Oncology's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 2, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 13, 2026before the open––-$0.40Release
Q1 FY2026ended Mar 31, 2026May 14, 2026before the open––-$0.37Release
Q4 FY2025ended Dec 31, 2025Mar 23, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025before the open––-$0.35Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025after the close$2.80M––Release
Q1 FY2025ended Mar 31, 2025May 15, 2025before the open––-$0.35Release
Q4 FY2024ended Dec 31, 2024Mar 18, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open––-$0.35Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024after the close––-$0.29Release
Q1 FY2024ended Mar 31, 2024May 14, 2024before the open$16.10M–-$0.06Release
Q4 FY2023ended Dec 31, 2023Mar 21, 2024before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Pyxis Oncology has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Pyxis Oncology puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Pyxis Oncology filed with the SEC as exhibits to Form 8-K or 6-K

  1. 8-K exhibit EX-99.1
    Update
  2. Pyxis Oncology MICVO Clinical Update September 9, 2026 Exhibit 99.2
    Update
  3. Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
    Update
  4. Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
    Results
  5. Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
    Update
  6. Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
    Results
  7. Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
    Results
  8. Building a Differentiated ADC Company Nasdaq: PYXS ​ March 2026 Exhibit 99.2
    Results
  9. Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Update
  10. Pyxis Oncology MICVO R/M HNSCC Clinical Update December 2025 Exhibit 99.2
    Update
  11. Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
    Results
  12. Building a Differentiated ADC Company Nasdaq: PYXS ​ May 2025 Exhibit 99.2
    Results
  13. Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
    Results
  14. Building a Differentiated ADC Company Nasdaq: PYXS ​ May 2025 Exhibit 99.2
    Results
  15. Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
    Results